Pressemeddelelse fra Hansdotter Oy
Fepod’s technology has been developed for years, e.g. with funding from Business Finland at Aalto University, and early clinical studies of the technology have been completed at HUS. The testing equipment consists of a standard smart phone, an affordable, small potentiostat, and mass-produced and disposable sampling sensors. The machine-learning algorithms being developed by Fepod will make it possible to expand the business into new areas as the analysis database grows.
“Almaral’s significant investment will enable Fepod to take a step towards commercializing the technology. It allows us to begin the regulatory approval processes in both the United States and the EU. In addition to the capital we have received, we are very impressed with Almaral’s diverse team, which has a proven track record of building Finnish innovations into global success stories,” says Jussi Pyysalo, the founder and CEO of Fepod.
Almaral currently has about ten investment targets under active evaluation. The private equity investor’s new, holistic operating model has attracted a lot of interest, but rather than quantity, the company wants to focus on quality.
“Fepod was selected as our first investment because we recognized the company’s ambition and business opportunities. I am convinced that our expertise perfectly complements Fepod’s goals. We believe that the development of electrochemical point-of-care analytics will save huge amounts of money and lives worldwide,” says the CEO of Almaral, Dr. Maria Severina.
Fepod Oy Ltd was founded in February 2022 to commercialize the novel diagnostics method based on nano-carbon sensors, portable potentiostats and machine-learning algorithms. The founding team consists of the original core team from Aalto University as well as two co-founders who complement their skill sets.
Almaral invests in early-stage biotechnology and life science startups. Besides investment, Almaral offers guidance in risk management, building up long-term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.
Contact:
Fepod:
Jussi Pyysalo, CEO
+358 400 789328
Almaral:
Maria Severina, CEO
+358 405 540127
Læs hele pressemeddelelsen på Via Ritzau her: https://www.sttinfo.fi/tiedote/new-venture-capitalist-focusing-on-health-technology-makes-its-first-investment-in-point-of-care-analytics?releaseId=69943849
** Ovenstående pressemeddelelse er videreformidlet af Ritzau på vegne af tredjepart. Ritzau er derfor ikke ansvarlig for indholdet **
